BT2 (Bycus Therapeutics)

BT2 is a nuclease enzyme therapeutic currently in the early stages of development by Bycus Therapeutics, a biotechnology company based in India. As a nuclease, the compound is designed to catalyze the cleavage of phosphodiester bonds in nucleic acids. While it is a featured candidate in the company's enzyme-based pipeline, specific details regarding its precise molecular target (such as DNA or RNA), intended therapeutic indications, and current clinical development phase have not been publicly disclosed. The molecule represents part of a broader portfolio at Bycus that includes both novel small molecules and therapeutic enzymes.